Halozyme Therapeutics (HALO) Tops Q1 EPS by 8c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $102.92 -0.08%
Financial Fact:
Net income (loss): -28.95M
Today's EPS Names:
SCWO, HSAI, SYRS, More
Financial Fact:
Net income (loss): -28.95M
Today's EPS Names:
SCWO, HSAI, SYRS, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of $0.47, $0.08 better than the analyst estimate of $0.39. Revenue for the quarter came in at $162.14 million versus the consensus estimate of $180.51 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Klarna shares tumble on weak full-year revenue guidance
- Taylor Devices (TAYD) Misses Q4 EPS by 31c
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
